Susvimo is an FDA-approved eye implant for diabetic macular edema that may reduce monthly injections to just two treatments a year while maintaining vision outcomes.

(Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the first patient dosed in ...

DME is a diabetes complication that threatens your the clarity of your vision. But managing blood sugar, blood pressure, and ...

Severe, long-standing DME with cystoid changes, subretinal detachment, and high inflammatory cytokine burden tends to respond better to dual ANG2/VEGF-A inhibition than VEGF monotherapy. Faricimab ...

In both studies, Vabysmo was found to be noninferior to aflibercept, with average vision gains being comparable between the treatment groups. The Food and Drug Administration (FDA) has approved ...

The optic cup and macula of a 24-year-old female. Image is released to Wikimedia commons with patient consent. Imaged with a non-mydriatic fundus camera at Pacific University College of Optometry.

Resistant diabetic macular edema may necessitate transitioning from one intravitreal pharmacotherapy to another when the edema is persistent — a practice sometimes undertaken in clinical management.

Brolucizumab (Beovu) proved noninferior to aflibercept (Eylea) for visual outcomes among patients with diabetic macular edema (DME), the phase III KINGFISHER trial showed. In over 500 patients with ...

Researchers also suggest potential new genetic associations with macular edema, which warrant further research. A study published in Scientific Reports confirmed previously identified retinal ...

The trials are evaluating DURAVYU (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME).